R Majeti

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood
    Christopher Y Park
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, California 94304, USA
    Nat Protoc 3:1932-40. 2008
  2. ncbi Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell Stem Cell 1:635-45. 2007
  3. ncbi Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
    R Majeti
    Division of Hematology, Department of Internal Medicine, Cancer Center, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Palo Alto, CA 94305, USA
    Oncogene 30:1009-19. 2011
  4. ncbi CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell 138:286-99. 2009
  5. ncbi Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA Institute for Stem Cell Biology and Regenerative Medicine, Cancer Center, and Ludwig Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Cell 19:9-10. 2011
  6. ncbi Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305, USA
    Sci Transl Med 2:63ra94. 2010
  7. ncbi Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford University, Palo Alto, CA 94304, USA
    Cell 142:699-713. 2010
  8. ncbi Macrophages as mediators of tumor immunosurveillance
    Siddhartha Jaiswal
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, USA
    Trends Immunol 31:212-9. 2010
  9. ncbi Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
    Bruno C Medeiros
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA
    Leuk Res 34:594-7. 2010
  10. ncbi CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
    Siddhartha Jaiswal
    Ludwig Center at Stanford, Stanford Cancer Center, Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell 138:271-85. 2009

Collaborators

Detail Information

Publications16

  1. ncbi In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood
    Christopher Y Park
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, California 94304, USA
    Nat Protoc 3:1932-40. 2008
    ..Short-term and long-term engraftment is assessed 4-6 weeks and 10-12 weeks post-transplantation, respectively, with preparation and analysis time requiring 4-8 h at each time point...
  2. ncbi Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell Stem Cell 1:635-45. 2007
    ..Furthermore, we report the first prospective isolation of a population of candidate human multipotent progenitors, Lin-CD34+CD38-CD90-CD45RA- cord blood...
  3. ncbi Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
    R Majeti
    Division of Hematology, Department of Internal Medicine, Cancer Center, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Palo Alto, CA 94305, USA
    Oncogene 30:1009-19. 2011
    ..Moreover, monoclonal antibodies targeting CD44, CD123, and CD47 have demonstrated efficacy against AML LSC in xenotransplantation models. Hopefully, these antibodies will ultimately prove to be effective in the treatment of human AML...
  4. ncbi CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell 138:286-99. 2009
    ..In summary, increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC...
  5. ncbi Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA Institute for Stem Cell Biology and Regenerative Medicine, Cancer Center, and Ludwig Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Cell 19:9-10. 2011
    ..These findings have implications for therapeutic targeting of these cells...
  6. ncbi Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305, USA
    Sci Transl Med 2:63ra94. 2010
    ....
  7. ncbi Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford University, Palo Alto, CA 94304, USA
    Cell 142:699-713. 2010
    ..These antibodies synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers...
  8. ncbi Macrophages as mediators of tumor immunosurveillance
    Siddhartha Jaiswal
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, USA
    Trends Immunol 31:212-9. 2010
    ..These results implicate macrophages in the immunosurveillance of hematopoietic cells and leukemias. The ability of macrophages to phagocytose tumor cells might be exploited therapeutically by blocking the CD47-SIRPalpha interaction...
  9. ncbi Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
    Bruno C Medeiros
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA
    Leuk Res 34:594-7. 2010
    ..2). Differential karyotype and expression of certain antigens were noted in patients with de novo AML with inv(3)(q21q26.2) vs. those with inv(3)(q21q26.2)-containing blasts...
  10. ncbi CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
    Siddhartha Jaiswal
    Ludwig Center at Stanford, Stanford Cancer Center, Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell 138:271-85. 2009
    ..We conclude that CD47 upregulation is an important mechanism that provides protection to normal HSCs during inflammation-mediated mobilization, and that leukemic progenitors co-opt this ability in order to evade macrophage killing...
  11. ncbi Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Palo Alto, California, USA
    Cancer Res 71:1374-84. 2011
    ..These data provide preclinical support for the development of an anti-CD47 antibody therapy for treatment of human ALL...
  12. ncbi Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
    Ravindra Majeti
    Institute for Stem Cell Biology and Regenerative Medicine and Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Proc Natl Acad Sci U S A 106:3396-401. 2009
    ....
  13. ncbi The adhesion molecule esam1 is a novel hematopoietic stem cell marker
    A G Lisa Ooi
    Institute of Stem Cell Biology and Regenerative Medicine, Department of Pathology, Stanford University School of Medicine, California, USA
    Stem Cells 27:653-61. 2009
    ..These studies identify Esam1 as a novel, widely applicable HSC-selective marker and suggest that Esam1 may play roles in both HSC proliferation and lineage decisions...
  14. ncbi Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia
    Andrew J Gentles
    Department of Radiology, Lucas Center for MR Spectroscopy and Imaging, School of Medicine, Stanford University, Palo Alto, CA 94305, USA
    JAMA 304:2706-15. 2010
    ..This model has significant implications for the development of novel therapies, but its clinical relevance has yet to be determined...
  15. ncbi The juxtamembrane wedge negatively regulates CD45 function in B cells
    Michelle L Hermiston
    Department of Pediatrics, University of California, San Francisco, San Francisco, California 94143, USA
    Immunity 23:635-47. 2005
    ..Together, the results support a role for CD45 as a rheostat, with both positive and negative regulatory functions, that fine-tunes the signal transduction threshold at multiple checkpoints in B cell development...
  16. ncbi Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases
    Michelle L Hermiston
    Department of Pediatrics, The Howard Hughes Medical Institute, University of California, San Francisco, California 94143-0795, USA
    J Clin Invest 109:9-14. 2002